Cytosurge AG is an ETH Zurich spin-off Company based in Zurich, Switzerland. The vision of Cytosurge is to provide a new generation of tools to stimulate novel applications at the forefront of nanotechnology, life sciences and single cell biology.
The company develops the patented FluidFM technology and is present in all major markets throughout Europe, Asia and the Americas. Cytosurge AG is a passionate team of specialists with backgrounds in various disciplines from business, engineering, biology and computer science
| Attachment | Size |
|---|---|
 Cytosurge Brochure | 2.45 MB |
Designed for pharmacologists and molecular biologists, the FluidFM CRISPR is the most reliable and cell-friendly solution to edit the genome of adherent cells.
Unlike traditional transfection methods, benefit from requiring only a small number of starting cells thanks to high-viability...
The micropipette is the perfect choice for single cell adhesion, single cell isolation and manipulation of micro particles.
Applications requiring nanometer-sized apertures are met by Cytosurge's FluidFM nanopipette design.
Cytosurge's nanosyringe is developed for nano-injection into single cells and nano-extraction from single cells.
With the cutting-edge FluidFM SPECTRA system, have access to all major FluidFM bio applications enabled in just one instrument: perform unique nano-injection into single cells, isolation of single cells, nano-printing and single cell adhesion measurements and combine them to explore new...
Designed for pharmacologists and molecular biologists, the FluidFM QUANT system delivers any drug into living, adherent cells, while allowing a precise quantification of the injected dose, to ultimately study its effects at single-cell level.
Overcome the selectivity of the cell membrane...
